In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.06 a new company low.

Within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Viskase Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3260, from total ranking in the first quarter 2026 at 4518.

Explain Quick Ratio?
How much Cash & cash equivalents ENZN�s has?
What are ENZN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ENZN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	15296.01 %	20259.03 %	3989.63 %	23.29 %	95.85 %
Y / Y Cash & cash equivalent Change	-82.14 %	-36.35 %	-80.33 %	-7.24 %	-4.19 %
Quick Ratio MRQ	0.06	0.25	0.13	80.1	55.16
ENZN's Total Ranking	# 3260	# 4518	# 84	# 104	# 79
Seq. Current Liabilities Change	9.61 %	64.36 %	12608.15 %	-32.75 %	44.95 %
Seq. Cash & cash equivalent Change	-72.36 %	210.5 %	-78.69 %	-2.34 %	-1.49 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 868
Overall Market	# 3979

Quick Ratio Statistics
High	Average	Low
127.03	42.89	0.06
(Sep 30 2021)		(Jun 30 2026)

Financial Statements
Viskase Holdings Inc 's Current Liabilities	$ 124 Millions	Visit ENZN's Balance sheet
Viskase Holdings Inc 's Cash & cash equivalent	$ 8 Millions	Visit ENZN's Balance sheet
Source of ENZN's Sales		Visit ENZN's Sales by Geography

Cumulative Viskase Holdings Inc 's Quick Ratio

ENZN's Quick Ratio for the trailling 12 Months

ENZN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	8698.82 %	5833.64 %	2214.44 %	15.96 %	13.83 %
Y / Y Cash & cash equivalent TTM Growth	-51.3 %	-32.11 %	-23.68 %	-3.49 %	-1.63 %
Quick Ratio TTM	0.29	0.69	2.01	50.17	52.62
Total Ranking TTM	# 2280	# 1988	# 5	# 5	# 6
Seq. Current Liabilities TTM Growth	67.21 %	159.15 %	1872.62 %	2.94 %	12.76 %
Seq. Cash & cash equivalent TTM Growth	-29.02 %	-11.53 %	-20.99 %	-1.85 %	-1.05 %

Quick ratio ranking by company, industry and sector >> Back to ENZN Financial Strength Comparisons >> Go to Compare ENZN Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $123.63 millions, cumulative Quick Ratio decreased to 0.29 below the Viskase Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Viskase Holdings Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3938.

Explain Quick Ratio?
How much Cash & cash equivalents ENZN�s has?
What are ENZN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 144
Healthcare Sector	# 908
Within the Market	# 3260

trailing twelve months Quick Ratio Statistics
High	Average	Low
121.09	31.25	0.2
(Jun 30 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions
Bioatla Inc	0.06	$ 1.544 Millions	$ 23.951 Millions
Viskase Holdings inc	0.06	$ 7.911 Millions	$ 123.630 Millions
Biomx Inc	0.06	$ 0.585 Millions	$ 10.180 Millions
Tevogen Bio Holdings Inc	0.06	$ 1.082 Millions	$ 19.573 Millions
Phoenix Biotech Acquisition Corp	0.03	$ 0.888 Millions	$ 32.405 Millions

Date modified: 2026-09-13T23:24:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.